From: Brennan, Patrick (OS/ASPA	(b) (6) >	
Sent: Wednesday, April 29, 2020	10:33 AM	
To: Fritz, Craig (NIH/OD) [E]	(b) (டி>; Burklow, Joh	n (NIH/OD) [E]
(b) (6) >; Myles, F	Renate (NIH/OD) [E]	(b) (6); Fine,
Amanda (NIH/OD) [E]	(b) (6)>; Wojtowicz, Emi	ma (NIH/OD) [E]
(b) (6) >; Ch	arrow, Robert (HHS/OGC)	(b) (6
Cc: Pence, Laura (HHS/ASL)	(b) (6) >; Hall, Bill (HHS/ASPA)
(b) (6) >; Pratt, Micl	nael (OS/ASPA)	(b) (б) >; Blakeman,
Scott (OS/ASPA) <	(b) (6)>	
NIH and Mr. Charrow,		
Below and in the attached is a dr	aft statement from the Secreta	ary regarding the
Below and in the attached is a dr Remdesivir trial – please let me k		
	now as soon as you can if this	
Remdesivir trial – please let me k	now as soon as you can if this	
Remdesivir trial – please let me k frontmatter from the NIH press r	now as soon as you can if this	



Patrick Brennan

Director of Speechwriting
Department of Health and Human Services
Office: (b) (6) | Cell (b) (6)